Melphalan and Ifex drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Melphalan (melphalan) and Ifex (ifosfamide). Common drug interactions include acute myeloid leukaemia among females and myelodysplastic syndrome among males.

The phase IV clinical study analyzes what interactions people have when they take Melphalan and Ifex. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Melphalan?

Melphalan has active ingredients of melphalan. eHealthMe is studying from 20,052 Melphalan users. Check the latest studies of Melphalan.

What is Ifex?

Ifex has active ingredients of ifosfamide. eHealthMe is studying from 829 Ifex users. Check the latest studies of Ifex.

On Jul, 08, 2026

12 people who take Melphalan and Ifex together, and have interactions are studied.

What are the common drug interactions of Melphalan and Ifex, by gender? *:

female:

Acute myeloid leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts)
Anaemia (lack of blood)
Blood creatinine increased
Death
Delayed puberty
Diarrhoea
Febrile neutropenia (fever with reduced white blood cells)
Growth retardation (delayed growth)
Intermittent claudication
Myelodysplastic syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged)

male:

Myelodysplastic syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged)
Stem cell transplant
Second primary malignancy (after getting cure a cancer, a new cancer development)

What are the common drug interactions of Melphalan and Ifex, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Anaemia (lack of blood)
Blood creatinine increased
Death
Delayed puberty
Diarrhoea
Febrile neutropenia (fever with reduced white blood cells)
Growth retardation (delayed growth)
Intermittent claudication
Myelodysplastic syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged)
Nausea (feeling of having an urge to vomit)

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Myelodysplastic syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged)
Stem cell transplant

60+:

n/a

What are the existing conditions these people have? *

Bone Marrow Conditioning Regimen: 8 people, 66.67%
Transplant Failure (transplantation failed to meet outcome): 7 people, 58.33%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 7 people, 58.33%
Multiple Myeloma (cancer of the plasma cells): 4 people, 33.33%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 2 people, 16.67%
Synovial Sarcoma (tumour of synovial membrane of joint): 1 person, 8.33%
Sarcoma (rare cancers that develop in the muscle, bone, nerves, cartilage, tendons, blood vessels and the fatty and fibrous tissues): 1 person, 8.33%
Neuroblastoma (a cancer that forms in your nerve tissue): 1 person, 8.33%
Ewing's Sarcoma Recurrent (malignant small, round, blue cell tumour- recurrent): 1 person, 8.33%
Ewing's Sarcoma Metastatic (malignant small, round, blue cell tumour-metastatic): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Melphalan and Ifex?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously